Key result
Glimepiride or gliclazide linked to ~85% lower early post-MI mortality vs. glyburide in T2D.
Answers are grounded in this paper and cite their sources.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Matthew C. Riddle (2010) conducted an editorial in Type 2 diabetes hospitalized for myocardial infarction (n=1,310). Glimepiride or gliclazide vs. Glyburide was evaluated on Early mortality (OR 0.15, 95% CI 0.04-0.56, p=0.005). Among patients with type 2 diabetes hospitalized for myocardial infarction, exposure to glimepiride or gliclazide was associated with lower early mortality than glyburide (OR 0.15; 95% CI 0.04-0.56).
Synapse has enriched 10 related papers. Consider them for comparative context: